Search results
Showing 106 to 120 of 233 results for children's cancer
Early value assessment (EVA) guidance on artificial intelligence technologies to aid contouring for radiotherapy treatment planning in people having external be...
View recommendations for HTE11Show all sections
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Biographies and interests register for the indicator advisory committee
This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults.
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Healthy start vitamins: special report on cost effectiveness (ECD5)
Healthy start vitamins: special report on cost effectiveness
Obesity in children and young people: prevention and lifestyle weight management programmes (QS94)
This quality standard covers preventing children and young people (under 18) from becoming overweight or obese, including strategies to increase physical activity and promote a healthy diet in the local population. It also covers lifestyle weight management programmes for children and young people who are overweight or obese. It describes high-quality care in priority areas for improvement.
View quality statements for QS94Show all sections
Sections for QS94
- Introduction
- List of quality statements
- Quality statement 1: Vending machines
- Quality statement 2: Nutritional information at the point of choosing food and drink options
- Quality statement 3: Prominent placement of healthy options
- Quality statement 4: Maintaining details of local lifestyle weight management programmes
- Quality statement 5: Raising awareness of lifestyle weight management programmes
- Quality statement 6: Family involvement in lifestyle weight management programmes
Find out more about NICE technology appraisals advisory committee D members
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)
Pelvic floor dysfunction: prevention and non-surgical management (NG210)
This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.
MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease